<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Endometrial carcinoma: Epidemiology, risk factors, and prevention
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Endometrial carcinoma: Epidemiology, risk factors, and prevention
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Endometrial carcinoma: Epidemiology, risk factors, and prevention
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lee-may Chen, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan S Berek, MD, MMS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara Goff, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Don S Dizon, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 31, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H622886219">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine cancer is the second most common gynecologic cancer worldwide when both resource-abundant and resource-limited countries are considered (cervical cancer is more common in worldwide statistics) [
         <a href="#rid1">
          1
         </a>
         ]. Over 90 percent of uterine cancers are endometrial, originating in the epithelium; most of the remainder are mesenchymal, originating in the myometrial muscle or, less commonly, the endometrial stroma [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The major risk factor for endometrial carcinoma (EC) is the presence of a clinical scenario associated with an excess of endogenous or exogenous estrogen without adequate opposition by a progestin. Lynch syndrome (hereditary nonpolyposis colon cancer) is a genetic risk factor; the pathogenesis in these cases is a germline mutation in one of the DNA mismatch repair genes.
        </p>
        <p>
         This topic will discuss the epidemiology, risk factors, and prevention of EC. Related topics are reviewed separately, including the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histopathology, genomic subtypes, and pathogenesis (see
         <a class="medical medical_review" href="/z/d/html/3192.html" rel="external">
          "Endometrial cancer: Pathology and classification"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical features, diagnosis, and screening for high-risk patients (see
         <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">
          "Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Staging and surgical treatment (see
         <a class="medical medical_review" href="/z/d/html/3251.html" rel="external">
          "Endometrial carcinoma: Staging and surgical treatment"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adjuvant therapy (see
         <a class="medical medical_review" href="/z/d/html/16917.html" rel="external">
          "Overview of resectable endometrial carcinoma", section on 'Role of adjuvant therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Issues related to Lynch syndrome are also reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">
          "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Genetics'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3224.html" rel="external">
          "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and prevention of endometrial and ovarian cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2843185480">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         EC develops in approximately 3 percent of females in the United States [
         <a href="#rid3">
          3
         </a>
         ] and is the fourth most common cancer among females in the United States after cancer of the breast, lung/bronchus, and colon/rectum [
         <a href="#rid4">
          4,5
         </a>
         ]. The incidence peaks between ages 60 and 70 years, but 2 to 5 percent of cases occur before age 40 years [
         <a href="#rid6">
          6
         </a>
         ]. Patients under age 50 who develop EC are often at risk because of chronic anovulation and/or obesity [
         <a href="#rid7">
          7-9
         </a>
         ].
        </p>
        <p>
         The incidence of EC has been increasing [
         <a href="#rid5">
          5,10
         </a>
         ], potentially due to a variety of factors, including the increasing prevalence of obesity [
         <a href="#rid11">
          11
         </a>
         ], decreasing use of menopausal hormone therapy with progestins, increasing prevalence of diabetes, and changes in reproductive behaviors (eg, increasing prevalence of nulliparity) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         In United States Surveillance, Epidemiology, and End Results (SEER) data (2015 to 2019), the age-adjusted incidence of EC was highest in Black females (29.3 per 100,000) compared with White females (28 per 100,000), Hispanic females (26 per 100,000), and Asian American females (22.6 per 100,000) [
         <a href="#rid13">
          13,14
         </a>
         ]. However, there was no adjustment for prevalence of hysterectomy; thus, these data likely underestimate the incidence of EC among females with an intact uterus. When hysterectomy prevalence is considered, Black females compared with White females continue to have a higher incidence of EC [
         <a href="#rid15">
          15
         </a>
         ], a higher incidence of aggressive endometrial cancers (clear cell, serous, high-grade endometrioid, malignant mixed Müllerian tumors), and a higher five-year mortality for nearly every stage and subtype of EC [
         <a href="#rid13">
          13
         </a>
         ]. The etiology of these differences is unknown and cannot be fully explained by known factors that vary by race [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         ECs are broadly classified into two major types that have different clinicopathologic characteristics and risk factors [
         <a href="#rid17">
          17,18
         </a>
         ]. This section will review risk factors for grade 1 and 2 endometrioid tumors, which comprise the majority (80 percent) of ECs. Such tumors, termed "nonaggressive" in the 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system [
         <a href="#rid19">
          19
         </a>
         ], and which largely overlap with "type I" EC in older classification systems, is stimulated by estrogen, typically preceded by endometrial hyperplasia (also referred to as endometrial intraepithelial neoplasia [EIN]), usually presents at an early stage, and has a good prognosis. Although most experts focus on estrogen as a key in the pathogenetic pathway of endometrioid neoplasms, lack of exposure to progesterone is likely to be equally important. In menopausal patients, progesterone is secreted mostly by the adrenal glands, levels are very low (&lt;0.05 ng/mL), and levels decrease as patients age because of waning adrenal secretion. The increasing prevalence of obesity, decreasing use of menopausal hormone therapy with progestins, and changes in reproductive behaviors probably explain the increasing prevalence of these tumors.
        </p>
        <p>
         Risk factors for the less common histologies, which include FIGO grade 3 endometrioid histology and nonendometrioid histologies (eg, serous, clear cell, mixed cell, undifferentiated, carcinosarcoma), include lower body mass index [BMI], older age at diagnosis, parity, Black race, and a personal history of breast cancer; this is discussed in detail separately. These neoplasms (termed "aggressive" in the 2023 FIGO staging [
         <a href="#rid19">
          19
         </a>
         ], and largely overlapping with "type II" tumors in older classification systems) are not estrogen-sensitive, often occur in an atrophic endometrium, and have a poor prognosis. The reason for the increasing incidence of these neoplasms is unknown. (See
         <a class="medical medical_review" href="/z/d/html/3180.html" rel="external">
          "Endometrial carcinoma: Serous and clear cell histologies", section on 'Epidemiology and risk factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Chronically increased estrogen levels or estrogenic activity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary risk factor for endometrioid EC is long-term exposure to increased estrogen levels from an exogenous or endogenous source without adequate opposition by a progestin [
         <a href="#rid20">
          20-26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H844020">
         <span class="h3">
          Exogenous sources
         </span>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h4">
          Unopposed estrogen therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a patient with a uterus, systemic estrogen therapy from any route (oral, transdermal patch, vaginal ring) without concurrent administration of a progestin results in a markedly increased risk of developing EC precursors (EIN or hyperplasia with atypia) and EC. In a meta-analysis of randomized trials of hormone therapy in postmenopausal patients, the increased risk of developing endometrial hyperplasia (any type) was statistically significant after one year of use of moderate- or high-dose unopposed estrogen (odds ratios [OR] 8.4 and 10.7, respectively) and after 18 to 24 months of low-dose therapy (OR 2.4) [
         <a href="#rid27">
          27
         </a>
         ]. In addition, multiple case-control and prospective studies have reported an increased risk of EC in patients who used estrogen alone, with the increase in relative risk ranging from 1.5- to 10-fold, depending on the dose and duration of use [
         <a href="#rid28">
          28-32
         </a>
         ]. It has been estimated that the absolute risk of EC in postmenopausal patients is approximately 1 in 1000; thus, the absolute risk in patients taking unopposed estrogen increases to as high as 1 in 100 [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">
          "Menopausal hormone therapy: Benefits and risks", section on 'Endometrial hyperplasia and carcinoma'
         </a>
         .)
        </p>
        <p>
         Low-dose vaginal estrogen therapy is a common treatment for symptoms related to vulvovaginal atrophy. The systemic absorption of these preparations is small; thus, most do not have adverse effects on the endometrium, but some may require use of an opposing progestin because of high systemic estrogen levels. (See
         <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">
          "Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Use of an opposing progestogen'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H843977">
         <span class="h4">
          Tamoxifen
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          Tamoxifen
         </a>
         is a selective estrogen receptor modulator (SERM) with both agonist and antagonist properties, depending upon the individual target organ and circulating levels of serum estrogen [
         <a href="#rid33">
          33-35
         </a>
         ]. In endometrial tissue, it acts as an estrogen agonist in postmenopausal patients (who have low estrogen levels), whereas it acts as an estrogen antagonist in premenopausal patients (who have high estrogen levels). As a result, use of tamoxifen increases the risk of EC in postmenopausal patients, an effect that is dose- and duration-dependent. The risk of EC in premenopausal patients on tamoxifen has not been established. (See
         <a class="medical medical_review" href="/z/d/html/14204.html" rel="external">
          "Abnormal uterine bleeding and uterine pathology in patients on tamoxifen therapy", section on 'Endometrial and menstrual effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14204.html" rel="external">
          "Abnormal uterine bleeding and uterine pathology in patients on tamoxifen therapy"
         </a>
         .)
        </p>
        <p>
         The effect of concurrent administration of a progestin on the risk of EC in postmenopausal patients on
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         has not been well studied because many patients have progesterone receptor-positive breast cancer and use of a progestin would raise concern regarding increasing the risk of recurrence. There is moderate-quality evidence that the levonorgestrel-releasing intrauterine system reduces the incidence of benign endometrial polyps and endometrial hyperplasia in patients with breast cancer taking tamoxifen, but there are insufficient data on EC occurrence [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14204.html" rel="external">
          "Abnormal uterine bleeding and uterine pathology in patients on tamoxifen therapy"
         </a>
         .)
        </p>
        <p>
         The American College of Obstetricians and Gynecologists does not recommend routine screening for EC in patients on
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         but advises counseling them about the risks associated with tamoxifen, monitoring them closely for symptoms of endometrial hyperplasia or EC, and evaluating them if symptoms of EC occur [
         <a href="#rid37">
          37
         </a>
         ]. These issues are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">
          "Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening", section on 'Screening'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          Clomiphene
         </a>
         is a nonsteroidal triphenylethylene derivative; while it acts as a SERM (similar to
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         ), its primary action is its antiestrogen effect on the uterus. Data are inconsistent regarding whether ovulation induction for treatment of infertility, particularly with clomiphene citrate, is associated with an increased risk of EC. (See
         <a class="medical medical_review" href="/z/d/html/7400.html" rel="external">
          "Ovulation induction with clomiphene citrate"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7400.html" rel="external">
          "Ovulation induction with clomiphene citrate", section on 'Pharmacology/mechanisms of action'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7400.html" rel="external">
          "Ovulation induction with clomiphene citrate", section on 'Cancer risks'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Endogenous sources
         </span>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h4">
          Chronic anovulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronically anovulatory patients continue to produce sex steroid hormones but not cyclically. As a result, normal endometrial turnover does not occur, and chronic estrogen production unopposed by adequate progesterone production allows continued proliferation of the endometrium, which can lead to endometrial hyperplasia and EC. The menopausal transition and polycystic ovary syndrome (PCOS) are two common clinical settings associated with anovulation with endogenous production of unopposed estrogen. In both of these settings, the risk for development of endometrial hyperplasia and EC is increased. (See
         <a class="medical medical_review" href="/z/d/html/7395.html" rel="external">
          "Clinical manifestations and diagnosis of menopause", section on 'Menopausal transition'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults", section on 'Endometrial cancer risk'
         </a>
         .)
        </p>
        <p>
         Nulliparity and infertility have been associated with EC but do not appear to be independent risk factors; instead, the association is probably related to the high frequency of anovulatory cycles in infertile patients.
        </p>
        <p class="headingAnchor" id="H843677">
         <span class="h4">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with obesity have high levels of endogenous estrogen due to the conversion of androstenedione to
         <a class="drug drug_general" data-topicid="107870" href="/z/d/drug information/107870.html" rel="external">
          estrone
         </a>
         and the aromatization of androgens to estradiol, both of which occur in peripheral adipose tissue [
         <a href="#rid38">
          38
         </a>
         ]. Patients with obesity may also have lower circulating levels of sex hormone-binding globulin (leading to increased steroid hormone activity), alterations in the concentration of insulin-like growth factor and its binding proteins, and insulin resistance, all of which may contribute to the increased risk of EC in these patients [
         <a href="#rid39">
          39,40
         </a>
         ]. Patients without these metabolic abnormalities (ie, metabolically healthy patients with obesity) also appear to have an increased risk of EC [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         In a pooled analysis of individual patient data from 10 cohort and 14 case-control studies including over 14,000 EC cases and over 35,000 controls, the odds of type I EC (defined in the study as endometrioid adenocarcinoma, adenocarcinoma not otherwise specified, and adenocarcinoma with squamous differentiation) by body mass index (BMI) were: OR 1.5 for overweight (BMI 25.0 to &lt;30.0 kg/m
         <sup>
          2
         </sup>
         ), OR 2.5 for class 1 obesity (30.0 to &lt;35.0 kg/m
         <sup>
          2
         </sup>
         ), OR 4.5 for class 2 obesity (35.0 to 39.9 kg/m
         <sup>
          2
         </sup>
         ), and OR 7.1 for class 3 obesity (≥40.0 kg/m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid42">
          42
         </a>
         ]. For type II EC, the ORs were 1.2 for overweight, 1.7 for class 1 obesity, 2.2 for class 2 obesity, and 3.1 for class 3 obesity. A limitation of this study was that the definition of type I EC varied from the standard definition; type I is usually defined as endometrioid grades 1 and 2, and type II is all other grades and histologies.
        </p>
        <p>
         Others have reported the following: higher BMI is associated with the development of EC at a young age (&lt;45 years old) [
         <a href="#rid43">
          43
         </a>
         ]; the distribution of adipose tissue does not appear to be a factor in EC risk [
         <a href="#rid44">
          44-46
         </a>
         ]; obesity appears to play a similar role as a risk factor for EC in Black, Hispanic, and White patients [
         <a href="#rid47">
          47
         </a>
         ]; and patients with a BMI ≥40 kg/m
         <sup>
          2
         </sup>
         who develop EC are more likely to have a less aggressive histologic subtype (endometrioid 87 percent versus serous or clear cell 75 percent) compared with patients with a BMI &lt;30 kg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid48">
          48
         </a>
         ]. Accordingly, patients with class 3 obesity are more likely to present with stage I disease (77 versus 61 percent) or low-grade histology (44 versus 24 percent). Despite a propensity to low-stage and low-grade carcinoma, class 3 obesity is paradoxically associated with an increased risk of death in patients with EC [
         <a href="#rid49">
          49,50
         </a>
         ]. The reason is unclear but may be due to continued stimulation of metastatic cells by endogenous estrogen or may result from obesity-associated conditions, such as diabetes or cardiovascular disease [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H843444">
         <span class="h4">
          Estrogen-secreting tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Granulosa cell tumors of the ovary are the tumor type most likely to be associated with endometrial hyperplasia and EC. In patients with these tumors, endometrial hyperplasia is detected in 25 to 50 percent and EC in 5 to 10 percent [
         <a href="#rid53">
          53-55
         </a>
         ]. The ECs are usually early stage and well-differentiated [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16833.html" rel="external">
          "Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3645599489">
         <span class="h4">
          Early menarche and late menopause
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early age at menarche is a risk factor for EC in some studies; late menopause is less consistently associated with an increased risk of the disease [
         <a href="#rid20">
          20,57-61
         </a>
         ]. The underlying mechanism may be a prolonged duration of exposure to estrogen stimulation.
        </p>
        <p class="headingAnchor" id="H151807464">
         <span class="h2">
          Hereditary factors
         </span>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Lynch syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lynch syndrome (hereditary nonpolyposis colorectal cancer) is an autosomal dominant disorder caused by a germline mutation in one of several DNA mismatch repair genes. Patients with Lynch syndrome have up to a 71 percent lifetime risk of developing EC compared with 2.7 percent in the general population  (
         <a class="graphic graphic_table graphicRef52285" href="/z/d/graphic/52285.html" rel="external">
          table 1
         </a>
         ), and they account for 2 to 5 percent of all patients with EC [
         <a href="#rid62">
          62
         </a>
         ]. The mean age at EC diagnosis in patients with Lynch syndrome is 46 to 54 years compared with a mean age of 61 years in other patients. The majority of Lynch syndrome-associated EC is endometrioid histology and presents at an early stage, similar to sporadic EC.
        </p>
        <p>
         Lynch syndrome, including EC screening, EC cancer prevention strategies, and other cancers that occur with increased frequency in this population, is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">
          "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3224.html" rel="external">
          "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and prevention of endometrial and ovarian cancer", section on 'Endometrial cancer surveillance'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8894433">
         <span class="h3">
          Other potential heritable factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cowden syndrome (also known as Cowden disease or multiple hamartoma syndrome)
         </strong>
         – Patients with Cowden syndrome, an autosomal dominant disorder in which there is a mutation in the
         <em>
          PTEN
         </em>
         tumor suppressor gene, exhibit characteristic mucocutaneous lesions; have a high prevalence of uterine leiomyomas; and have an increased risk of endometrial, breast, thyroid, colorectal, and renal cancers. There are few data regarding this rare syndrome; a 13 to 19 percent lifetime risk of EC has been described [
         <a href="#rid63">
          63-65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">
          "PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Cowden syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First-degree relative with EC
         </strong>
         – In a meta-analysis of 16 comparative studies, patients with a first-degree relative with a history of EC were at increased risk of EC (relative risk 1.82, 95% CI 1.65-1.98) [
         <a href="#rid66">
          66
         </a>
         ]. The cumulative risk of EC to age 70 years in patients with an affected first-degree relative was estimated to be 3.1 percent compared with &lt;2 percent in the general population. However, only three of the studies excluded patients with Lynch syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           BRCA
          </em>
         </strong>
         <strong>
          carriers
         </strong>
         – The risk of uterine cancer in
         <em>
          BRCA
         </em>
         1 carriers, and consequently its role as part of the
         <em>
          BRCA
         </em>
         mutated syndrome, is debated [
         <a href="#rid67">
          67
         </a>
         ], and whether there is a small increase in risk of EC associated with pathogenic
         <em>
          BRCA
         </em>
         variants is unclear. Most or all of the observed increase may be attributable to use of
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         for prevention or treatment of breast cancer. (See
         <a class="medical medical_review" href="/z/d/html/758.html" rel="external">
          "Cancer risks and management of BRCA1/2 carriers without cancer", section on 'Other gynecologic malignancies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14204.html" rel="external">
          "Abnormal uterine bleeding and uterine pathology in patients on tamoxifen therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other germline mutations have also been described [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4078219948">
         <span class="h2">
          Uncertain risk factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phytoestrogens
         </strong>
         – Phytoestrogens are nonsteroidal compounds that occur naturally in many plants, fruits, and vegetables and have both estrogenic and antiestrogenic properties.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The effect of phytoestrogens on EC risk is unclear [
         <a href="#rid69">
          69,70
         </a>
         ]. The body of data from observational studies suggests no increased risk of endometrial hyperplasia or EC with phytoestrogen supplements or dietary intake and actually a decreased risk. In a meta-analysis of seven case-control and cohort studies including over 3500 patients with EC, high compared with low soy intake was associated with a 30 percent decrease in EC risk (OR 0.70, 95% CI 0.57-0.86) [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most randomized trials that have addressed this issue have had only 6 to 12 months of follow-up [
         <a href="#rid70">
          70
         </a>
         ]. In the only trial with longer follow-up, postmenopausal patients assigned to soy isoflavone supplements (150 mg/day) for five years had a higher rate of endometrial hyperplasia (detected by endometrial biopsy) compared with the placebo group (3.8 versus 0 percent) [
         <a href="#rid72">
          72
         </a>
         ]. However, the quality of this trial was limited since the total number of events was small (six cases endometrial hyperplasia: five simple and one complex) and the hyperplasias that developed were of generally low malignant potential. Endometrial hyperplasia with atypia and, less consistently, hyperplasia without atypia are the precursor lesions for EC. (See
         <a class="medical medical_review" href="/z/d/html/3217.html" rel="external">
          "Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis", section on 'Risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A history of breast cancer is a risk factor for developing EC, at least in part because of breast cancer treatment factors (eg,
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         use), shared behavioral factors (eg, obesity), and shared genetic susceptibility (eg, Cowden syndrome).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A history of pelvic radiation for treatment of primary rectal carcinoma may increase the risk for developing uterine cancer, although the overall incidence is small. In one cohort study including over 20,000 female patients with rectal cancer, treatment with radiotherapy plus surgery compared with surgery alone was associated with an increase in uterine corpus cancer (2.8 versus 1.0 percent, adjusted hazard ratio 3.06, 95% CI 2.1-4.4) after a five-year latency period [
         <a href="#rid73">
          73
         </a>
         ]. One limitation of this study is that it did not differentiate between types of uterine corpus cancers (eg, endometrial, uterine sarcoma). (See
         <a class="medical medical_review" href="/z/d/html/14230.html" rel="external">
          "Approach to the long-term survivor of colorectal cancer", section on 'Second malignancies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with diabetes mellitus and hypertension are at increased risk for developing EC [
         <a href="#rid74">
          74-76
         </a>
         ]. Comorbid factors, primarily obesity, account for much of this risk [
         <a href="#rid46">
          46,77
         </a>
         ], but some studies have found independent effects as well [
         <a href="#rid20">
          20,78-86
         </a>
         ]. In patients with diabetes, insulin resistance, chronic inflammation, and high free ovarian steroid hormone levels are possible mechanisms for the association [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The body of evidence suggests that menopausal hormone therapy with combined estrogen-progestin preparations does not increase the risk of endometrial hyperplasia, with one notable exception. An analysis of unpublished data from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial showed a statistically significant increase in endometrial hyperplasia after two years of cyclic combined therapy (3.3 versus 0 percent in the placebo group) [
         <a href="#rid27">
          27,88,89
         </a>
         ]. The regimen used in this trial was
         <a class="drug drug_general" data-topicid="9424" href="/z/d/drug information/9424.html" rel="external">
          conjugated equine estrogen
         </a>
         0.625 mg daily plus
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         10 mg for 12 days/month. The reporting of summary data for all histologic types of endometrial hyperplasia was a limitation of this analysis since hyperplasia with atypia is most likely to be associated with carcinoma. A further limitation of this study was inclusion of only oral therapy; thus, it is uncertain whether the results can be generalized to nonoral hormone therapy (patches or vaginal rings). Summary data for the risk of EC were not reported for most interventions in this analysis because there were too few events. (See
         <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">
          "Menopausal hormone therapy: Benefits and risks", section on 'Protective effect of progestins'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Certain chemicals, such as those found in hair straighteners, may be associated with increased rates of EC [
         <a href="#rid90">
          90
         </a>
         ], but evidence is limited and further study is needed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          PROTECTIVE FACTORS
         </span>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Use of hormonal contraception
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of estrogen-progestin oral contraceptives (OCs) decreased the risk of EC by 30 to 40 percent in large epidemiologic studies, and the risk reduction persisted for years after discontinuation [
         <a href="#rid91">
          91,92
         </a>
         ]. This benefit, which likely applies to nonoral estrogen-progestin contraceptives as well, is attributed to the progestin component, which suppresses endometrial proliferation. Progestin-only contraceptives (eg, depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         , progestin implants, progestin-releasing intrauterine devices [IUD]) appear to provide even greater protection against development of EC in epidemiologic studies [
         <a href="#rid93">
          93-95
         </a>
         ]. However, in older studies, OCs contained higher estrogen doses than contemporary preparations, which are progestin-dominant and thus may have protective effects comparable to progestin-only contraceptives. (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Noncontraceptive benefits'
         </a>
         .)
        </p>
        <p>
         Because of their strong antagonistic effects on endometrial proliferation, progestins have also been used to treat endometrial hyperplasia and early EC. (See
         <a class="medical medical_review" href="/z/d/html/16723.html" rel="external">
          "Endometrial hyperplasia: Management and prognosis", section on 'Progestin therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/101430.html" rel="external">
          "Fertility preservation in patients with endometrial carcinoma", section on 'Progestin therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1859311181">
         <span class="h2">
          Other potential protective factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increasing gravidity and parity
         </strong>
         – The risk of EC is inversely related to gravidity and parity [
         <a href="#rid57">
          57,96-98
         </a>
         ]. As an example, a nationwide, register-based cohort study from Denmark observed that a first pregnancy was associated with a reduced risk of EC, and the reduction was observed whether it ended in induced abortion (adjusted relative risk [aRR] 0.53, 95% CI 0.45-0.64) or childbirth (aRR 0.66, 95% CI 0.61-0.72) [
         <a href="#rid98">
          98
         </a>
         ]. In addition, each subsequent pregnancy was associated with additional reductions in risk, possibly because of the role of progesterone activity throughout pregnancy. A limitation of this study was that information on lifetime use of OCs was not available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Older age at last birth
         </strong>
         – Childbearing at an older age, independent of parity and other factors, was associated with a decreased risk of EC in a meta-analysis of individual data from 17 studies that included over 8000 cases of EC [
         <a href="#rid99">
          99
         </a>
         ]. A significant decrease in risk was found per five years of increasing age at last birth (odds ratio [OR] 0.87, 95% CI 0.85-0.90); rate of EC in patients with last birth at age &lt;25 years was used as the reference standard. As an example, patients who last gave birth at ages 35 to 39 years had a 32 percent decrease in risk (95% CI 0.61-0.76). The reason older age is protective is not known; we speculate that high progesterone levels during pregnancy may be an important protective factor as patients age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Breastfeeding
         </strong>
         – In a meta-analysis of 17 studies including nearly 9000 patients with EC from several countries, ever-breastfeeding was associated with an 11 percent reduction (OR 0.89, 95% CI 0.81-0.98) in EC compared with parous patients who did not breastfeed [
         <a href="#rid100">
          100
         </a>
         ]. In terms of average duration of breastfeeding per child, it appeared that at least three months were required to be associated with decreased EC risk, and the degree of risk did not continue to decrease after six to nine months. The association with ever-breastfeeding was not impacted by greater parity, body mass index, or histologic subtype. The reason breastfeeding is protective is not known; we speculate that low estrogen levels during breastfeeding may have a protective role. (See
         <a class="medical medical_review" href="/z/d/html/5022.html" rel="external">
          "Maternal and economic benefits of breastfeeding"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Smoking
         </strong>
         – Cigarette smoking is associated with a decreased risk of developing EC in postmenopausal, but not premenopausal, patients [
         <a href="#rid101">
          101
         </a>
         ]. Obviously, the major health risks associated with tobacco use far outweigh this benefit. The mechanism suggested for this effect is that smoking stimulates hepatic metabolism of estrogens, leading to a reduced incidence of endometrial abnormalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical activity and diet
         </strong>
         – Meta-analyses have observed a decreased risk of EC with increased physical activity [
         <a href="#rid102">
          102,103
         </a>
         ]. Several plausible biological mechanisms have been proposed to explain a possible association between high levels of physical activity and reduced cancer risk; these include decreased obesity and central adiposity and favorable changes in immune function and in endogenous sexual and metabolic hormone levels and growth factors [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A meta-analysis of comparative studies noted a decreased risk of EC proportional to the quantity of coffee consumed [
         <a href="#rid105">
          105
         </a>
         ]. Another noted a decreased risk of EC proportional to the quantity of tea consumed and suggested that consumption of green tea was more protective than consumption of black tea [
         <a href="#rid106">
          106,107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          Copper IUD
         </a>
         – As with hormonal contraception, the copper IUD may also be associated with lower rates of endometrial carcinoma [
         <a href="#rid108">
          108
         </a>
         ]. Copper induces a cytotoxic inflammatory response within the endometrium which may reduce rates of endometrial hyperplasia. (See
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types", section on 'Copper IUD'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1549568796">
         <span class="h1">
          STRATEGIES FOR PREVENTION
         </span>
        </p>
        <p class="headingAnchor" id="H3511320042">
         <span class="h2">
          Patients at highest risk
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with Lynch syndrome
         </strong>
         – Preventive strategies include chemoprevention with oral contraceptive pills (estimated 50 to 60 percent reduction in EC); progestin-only contraceptives (including intrauterine systems) are also likely to be effective. When childbearing is complete, risk-reducing total hysterectomy is recommended. (See
         <a class="medical medical_review" href="/z/d/html/3224.html" rel="external">
          "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and prevention of endometrial and ovarian cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients taking
         </strong>
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         – Use of the levonorgestrel-releasing intrauterine system has been proposed for prevention and treatment of uterine pathology in patients on tamoxifen. However, the safety of this treatment in patients with progesterone receptor-positive breast cancer has not been established. Use must be individualized and discussed with the patient's oncologist. (See
         <a class="medical medical_review" href="/z/d/html/14204.html" rel="external">
          "Abnormal uterine bleeding and uterine pathology in patients on tamoxifen therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with polycystic ovary syndrome
         </strong>
         – Combined estrogen-progestin oral contraceptives are the first-line therapy for endometrial protection as they also treat hyperandrogenism and menstrual dysfunction and provide contraception. (See
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults", section on 'Endometrial protection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with obesity
         </strong>
         – Weight reduction through lifestyle modifications (diet and physical activity) or bariatric surgery can reduce obesity. Bariatric surgery has been associated with 50 to 80 percent reductions in occurrence of EC in large studies and a meta-analysis of controlled studies [
         <a href="#rid109">
          109-111
         </a>
         ]. Progestin-dominant contraceptives are also likely to be protective. (See
         <a class="medical medical_review" href="/z/d/html/90469.html" rel="external">
          "Outcomes of bariatric surgery", section on 'Cancer risk and mortality'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1102146938">
         <span class="h2">
          Patients at average risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients at average risk for developing EC can minimize this risk by achieving and maintaining a normal body mass index, engaging in regular physical activity, breastfeeding rather than formula feeding, and using hormonal rather than nonhormonal contraceptives. All of these behaviors have health benefits beyond protection of the endometrium.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">
          "Overweight and obesity in adults: Health consequences"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2786.html" rel="external">
          "The benefits and risks of aerobic exercise", section on 'Cancer prevention and treatment'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5022.html" rel="external">
          "Maternal and economic benefits of breastfeeding", section on 'Cancer'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Noncontraceptive uses'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">
          "Intrauterine contraception: Candidates and device selection", section on 'Endometrial protection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types", section on 'Noncontraceptive benefits'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2152626864">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121144.html" rel="external">
          "Society guideline links: Uterine cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H38">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15422.html" rel="external">
          "Patient education: Uterine cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/866.html" rel="external">
          "Patient education: Endometrial cancer diagnosis, staging, and surgical treatment (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/871.html" rel="external">
          "Patient education: Endometrial cancer treatment after surgery (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Endometrial carcinoma (EC) develops in approximately 3 percent of females in the United States and is the fourth most common cancer among females in the United States after cancer of the breast, lung/bronchus, and colon/rectum. The incidence peaks between ages 60 and 70 years, but 2 to 5 percent of cases occur before age 40 years. Patients under age 50 who develop EC are often at risk because of chronic anovulation and/or obesity or genetic predisposition (eg, Lynch syndrome). (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Types
         </strong>
         – ECs are broadly classified by the International Federation of Gynecology and Obstetrics (FIGO) staging system into two major types that have different clinicopathologic characteristics and risk factors:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nonaggressive
         </strong>
         – These neoplasms have low-grade (FIGO grades 1 and 2) endometrioid histology and comprise the majority (80 percent) of ECs; this category largely overlaps with "type I" EC in older classification systems. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Aggressive
         </strong>
         – These neoplasms (FIGO grade 3 endometrioid histology and nonendometrioid histologies: serous, clear cell, mixed cell, undifferentiated, carcinosarcoma) are less common and are typically not estrogen-sensitive. This category largely overlaps with "type II" EC in older classification systems and is reviewed separately. (See
         <a class="local">
          'Risk factors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3180.html" rel="external">
          "Endometrial carcinoma: Serous and clear cell histologies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The primary risk factor for grade 1 and 2 endometrioid EC is long-term exposure to increased estrogen levels from an exogenous or endogenous source (eg, chronic anovulation, obesity, estrogen-secreting tumors, early menarche, late menopause) without adequate opposition by a progestin. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         By contrast, patients with "aggressive" tumors tend to be older at diagnosis, have a lower body mass index (BMI), and parous. Black race and a personal history of breast cancer also appear to be risk factors for such cancers. (See
         <a class="local">
          'Risk factors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3180.html" rel="external">
          "Endometrial carcinoma: Serous and clear cell histologies", section on 'Epidemiology and risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Protective factors
         </strong>
         – Estrogen-progestin or progestin-only contraceptives are protective factors against development of grade 1 and 2 endometrioid EC. (See
         <a class="local">
          'Protective factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Strategies of prevention of both types of EC depend, in part, on whether patients are at high or average risk for developing EC as well as their underlying risk factors. Hysterectomy is the most aggressive approach; more conservative approaches include achieving and maintaining a normal body mass index and using progestin-dominant contraceptives. (See
         <a class="local">
          'Strategies for prevention'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71:209.
          </a>
         </li>
         <li class="breakAll">
          https://www.cancer.net/cancer-types/uterine-cancer/statistics.
         </li>
         <li class="breakAll">
          Cancer stat facts: Uterine cancer. National Cancer Institute. Available at: https://seer.cancer.gov/statfacts/html/corp.html (Accessed on June 01, 2022).
         </li>
         <li class="breakAll">
          American Cancer Society. Cancer Facts &amp; Figures 2019. Atlanta: American Cancer Society; 2019 http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf (Accessed on October 16, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74:12.
          </a>
         </li>
         <li class="breakAll">
          Epidemiology of Endometrial Cancer Consortium (E2C2) https://epi.grants.cancer.gov/eecc/ (Accessed on October 10, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 2005; 105:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmeler KM, Soliman PT, Sun CC, et al. Endometrial cancer in young, normal-weight women. Gynecol Oncol 2005; 99:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lachance JA, Everett EN, Greer B, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2006; 101:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Constantine GD, Kessler G, Graham S, Goldstein SR. Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors. J Womens Health (Larchmt) 2019; 28:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smrz SA, Calo C, Fisher JL, Salani R. An ecological evaluation of the increasing incidence of endometrial cancer and the obesity epidemic. Am J Obstet Gynecol 2021; 224:506.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cote ML, Ruterbusch JJ, Olson SH, et al. The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women. Cancer Epidemiol Biomarkers Prev 2015; 24:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke MA, Devesa SS, Hammer A, Wentzensen N. Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. JAMA Oncol 2022; 8:895.
          </a>
         </li>
         <li class="breakAll">
          Cancer stat facts: uterine cancer. Centers for Disease Control and Prevention. Available at: https://seer.cancer.gov/statfacts/html/corp.html (Accessed on July 08, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamison PM, Noone AM, Ries LA, et al. Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev 2013; 22:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarink D, Wilkens LR, White KK, et al. Racial/ethnic differences in anthropometric and hormone-related factors and endometrial cancer risk: the Multiethnic Cohort Study. Br J Cancer 2021; 124:1724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 2010; 21:1851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023; 162:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 1992; 167:1317.
          </a>
         </li>
         <li class="breakAll">
          American College of Obstetricians and Gynecologists Committee on Gynecologic Practice: Tamoxifen and endometrial Cancer. Committee opinion 232. ACOG 2000; Washington, DC.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001; 84:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004; 108:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyholm HC, Nielsen AL, Lyndrup J, et al. Plasma oestrogens in postmenopausal women with endometrial cancer. Br J Obstet Gynaecol 1993; 100:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996; 88:1127.
          </a>
         </li>
         <li class="breakAll">
          Hacker NF, Friedlander ML. Uterine Cancer. In: Berek &amp; Hacker’s Gynecologic Oncology, 7th ed, Berek JS, Hacker NF (Eds), Lippincott Williams &amp; Wilkins, 2020. p.371.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furness S, Roberts H, Marjoribanks J, et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2009; :CD000402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol 1989; 161:1859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strom BL, Schinnar R, Weber AL, et al. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 2006; 164:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riggs BL, Hartmann LC. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med 2003; 348:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mourits MJ, De Vries EG, Willemse PH, et al. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001; 97:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein SR. The effect of SERMs on the endometrium. Ann N Y Acad Sci 2001; 949:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dominick S, Hickey M, Chin J, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev 2015; :CD007245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee Opinion No. 601: Tamoxifen and uterine cancer. Obstet Gynecol 2014; 123:1394. Reaffirmed 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr 1987; 45:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 1996; 88:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005; 366:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao Z, Zheng X, Yang H, et al. Association of obesity status and metabolic syndrome with site-specific cancers: a population-based cohort study. Br J Cancer 2020; 123:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 2013; 31:2607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pellerin GP, Finan MA. Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis. Am J Obstet Gynecol 2005; 193:1640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gredmark T, Kvint S, Havel G, Mattsson LA. Adipose tissue distribution in postmenopausal women with adenomatous hyperplasia of the endometrium. Gynecol Oncol 1999; 72:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Folsom AR, Kaye SA, Potter JD, Prineas RJ. Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: early findings of the Iowa Women's Health Study. Cancer Res 1989; 49:6828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindemann K, Vatten LJ, Ellstrøm-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer 2008; 98:1582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setiawan VW, Pike MC, Kolonel LN, et al. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J Epidemiol 2007; 165:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Everett E, Tamimi H, Greer B, et al. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2003; 90:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009; 114:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Abid S, Szold A, Klausner J. Obesity and cancer. J Med 2002; 33:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schouten LJ, Goldbohm RA, van den Brandt PA. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J Natl Cancer Inst 2004; 96:1635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003; 21:1180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanagnolo V, Pasinetti B, Sartori E. Clinical review of 63 cases of sex cord stromal tumors. Eur J Gynaecol Oncol 2004; 25:431.
          </a>
         </li>
         <li class="breakAll">
          Berek &amp; Hacker’s Gynecologic Oncology, 7th ed, Berek JS, Hacker NF (Eds), Lippincott Williams &amp; Wilkins, 2020.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans AT 3rd, Gaffey TA, Malkasian GD Jr, Annegers JF. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 1980; 55:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McPherson CP, Sellers TA, Potter JD, et al. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol 1996; 143:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu WH, Xiang YB, Ruan ZX, et al. Menstrual and reproductive factors and endometrial cancer risk: Results from a population-based case-control study in urban Shanghai. Int J Cancer 2004; 108:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Vecchia C, Franceschi S, Decarli A, et al. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst 1984; 73:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karageorgi S, Hankinson SE, Kraft P, De Vivo I. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. Int J Cancer 2010; 126:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katagiri R, Iwasaki M, Abe SK, et al. Reproductive Factors and Endometrial Cancer Risk Among Women. JAMA Netw Open 2023; 6:e2332296.
          </a>
         </li>
         <li class="breakAll">
          NCCN. Cancer risks in Lynch syndrome by gene compared to the general population. version 3.2019 https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (Accessed on January 13, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010; 139:1927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riegert-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract 2010; 8:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet 2011; 48:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol 2015; 125:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shu CA, Pike MC, Jotwani AR, et al. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncol 2016; 2:1434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wen H, Xu Q, Sheng X, et al. Prevalence and Landscape of Pathogenic or Likely Pathogenic Germline Variants and Their Association With Somatic Phenotype in Unselected Chinese Patients With Gynecologic Cancers. JAMA Netw Open 2023; 6:e2326437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horn-Ross PL, John EM, Canchola AJ, et al. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst 2003; 95:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           North American Menopause Society. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Menopause 2011; 18:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myung SK, Ju W, Choi HJ, et al. Soy intake and risk of endocrine-related gynaecological cancer: a meta-analysis. BJOG 2009; 116:1697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unfer V, Casini ML, Costabile L, et al. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril 2004; 82:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guan X, Wei R, Yang R, et al. Association of Radiotherapy for Rectal Cancer and Second Gynecological Malignant Neoplasms. JAMA Netw Open 2021; 4:e2031661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer 2003; 104:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 2010; 24:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007; 50:1365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 1998; 148:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soler M, Chatenoud L, Negri E, et al. Hypertension and hormone-related neoplasms in women. Hypertension 1999; 34:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soliman PT, Wu D, Tortolero-Luna G, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 2006; 106:2376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zendehdel K, Nyrén O, Ostenson CG, et al. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003; 95:1797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiderpass E, Persson I, Adami HO, et al. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 2000; 11:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Vecchia C, Negri E, Franceschi S, et al. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994; 70:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parazzini F, La Vecchia C, Negri E, et al. Diabetes and endometrial cancer: an Italian case-control study. Int J Cancer 1999; 81:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev 2007; 16:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucenteforte E, Bosetti C, Talamini R, et al. Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension. Br J Cancer 2007; 97:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Liu Z, Yu X, et al. The association between metabolic abnormality and endometrial cancer: a large case-control study in China. Gynecol Oncol 2010; 117:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anastasi E, Filardi T, Tartaglione S, et al. Linking type 2 diabetes and gynecological cancer: an introductory overview. Clin Chem Lab Med 2018; 56:1413.
          </a>
         </li>
         <li class="breakAll">
          Furness S, University of Manchester, Manchester England, personal communication regarding unpublished data from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, 2009.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004; 94:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang CJ, O'Brien KM, Keil AP, et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst 2022; 114:1636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 2015; 16:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol 2017; 216:580.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cullins VE. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. J Reprod Med 1996; 41:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 1996; 41:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soini T, Hurskainen R, Grénman S, et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 2014; 124:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Løchen ML, Lund E. Childbearing and mortality from cancer of the corpus uteri. Acta Obstet Gynecol Scand 1997; 76:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parazzini F, Negri E, La Vecchia C, et al. Role of reproductive factors on the risk of endometrial cancer. Int J Cancer 1998; 76:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husby A, Wohlfahrt J, Melbye M. Pregnancy duration and endometrial cancer risk: nationwide cohort study. BMJ 2019; 366:l4693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setiawan VW, Pike MC, Karageorgi S, et al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. Am J Epidemiol 2012; 176:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan SJ, Na R, Johnatty SE, et al. Breastfeeding and Endometrial Cancer Risk: An Analysis From the Epidemiology of Endometrial Cancer Consortium. Obstet Gynecol 2017; 129:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou B, Yang L, Sun Q, et al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med 2008; 121:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmid D, Behrens G, Keimling M, et al. A systematic review and meta-analysis of physical activity and endometrial cancer risk. Eur J Epidemiol 2015; 30:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore SC, Gierach GL, Schatzkin A, Matthews CE. Physical activity, sedentary behaviours, and the prevention of endometrial cancer. Br J Cancer 2010; 103:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 2002; 132:3456S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bravi F, Scotti L, Bosetti C, et al. Coffee drinking and endometrial cancer risk: a metaanalysis of observational studies. Am J Obstet Gynecol 2009; 200:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang NP, Li H, Qiu YL, et al. Tea consumption and risk of endometrial cancer: a metaanalysis. Am J Obstet Gynecol 2009; 201:605.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butler LM, Wu AH. Green and black tea in relation to gynecologic cancers. Mol Nutr Food Res 2011; 55:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minalt N, Caldwell A, Yedlicka GM, et al. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review. Am J Obstet Gynecol 2023; 229:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackenzie H, Markar SR, Askari A, et al. Obesity surgery and risk of cancer. Br J Surg 2018; 105:1650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schauer DP, Feigelson HS, Koebnick C, et al. Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort. Ann Surg 2019; 269:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang X, Rhoades J, Caan BJ, et al. Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis. Int J Gynecol Cancer 2019; 29:1361.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3249 Version 64.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33538338" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33538338" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33538338" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33538338" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38230766" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cancer statistics, 2024.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38230766" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cancer statistics, 2024.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15738027" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Risk factors for young premenopausal women with endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16051336" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Endometrial cancer in young, normal-weight women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16413048" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30484734" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33127429" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : An ecological evaluation of the increasing incidence of endometrial cancer and the obesity epidemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26290568" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35511145" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35511145" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23239812" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33723396" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Racial/ethnic differences in anthropometric and hormone-related factors and endometrial cancer risk: the Multiethnic Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6822361" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Two pathogenetic types of endometrial carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20628804" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Factors associated with Type I and Type II endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37337978" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : FIGO staging of endometrial cancer: 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1442985" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1442985" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11286480" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14648710" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8297845" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Plasma oestrogens in postmenopausal women with endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8757192" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Case-control study of endogenous steroid hormones and endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8757192" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Case-control study of endogenous steroid hormones and endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19370558" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hormone therapy in postmenopausal women and risk of endometrial hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2690639" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The cancer question: an overview of recent epidemiologic and retrospective data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2538173" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15866308" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Endometrial cancer and hormone-replacement therapy in the Million Women Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10393721" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Risk of endometrial cancer following estrogen replacement with and without progestins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16997897" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12584371" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11336777" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Tamoxifen treatment and gynecologic side effects: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11795358" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The effect of SERMs on the endometrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26649916" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24848920" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Committee Opinion No. 601: Tamoxifen and uterine cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3541569" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Adipose tissue as a source of hormones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8637031" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16084259" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32728095" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Association of obesity status and metabolic syndrome with site-specific cancers: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23733771" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Type I and II endometrial cancers: have they different risk factors?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16260203" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10021291" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Adipose tissue distribution in postmenopausal women with adenomatous hyperplasia of the endometrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2819722" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: early findings of the Iowa Women's Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18362938" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17090617" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12821356" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19406460" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12711737" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12939106" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Obesity and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15523093" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12637488" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Granulosa cell tumor of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15285297" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Clinical review of 63 cases of sex cord stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15285297" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Clinical review of 63 cases of sex cord stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6243409" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Clinicopathologic review of 118 granulosa and 82 theca cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8651218" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14696129" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Menstrual and reproductive factors and endometrial cancer risk: Results from a population-based case-control study in urban Shanghai.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6590913" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Risk factors for endometrial cancer at different ages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19551854" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37669051" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Reproductive Factors and Endometrial Cancer Risk Among Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37669051" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Reproductive Factors and Endometrial Cancer Risk Among Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20600018" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20565722" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21659347" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25560109" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Family history and risk of endometrial cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27367496" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37523182" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prevalence and Landscape of Pathogenic or Likely Pathogenic Germline Variants and Their Association With Somatic Phenotype in Unselected Chinese Patients With Gynecologic Cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12902445" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Phytoestrogen intake and endometrial cancer risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21685820" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19775307" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Soy intake and risk of endocrine-related gynaecological cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15237003" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33416884" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Association of Radiotherapy for Rectal Cancer and Second Gynecological Malignant Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12640672" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20656522" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17476474" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Diabetes mellitus and risk of endometrial cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9690359" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Diabetes, body size, and risk of endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10454461" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Hypertension and hormone-related neoplasms in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16639730" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Association between adiponectin, insulin resistance, and endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14652242" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10710204" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7947103" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A case-control study of diabetes mellitus and cancer risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10225441" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Diabetes and endometrial cancer: an Italian case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17301260" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Diabetes and risk of endometrial cancer: a population-based prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17912243" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20096921" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The association between metabolic abnormality and endometrial cancer: a large case-control study in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29427549" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Linking type 2 diabetes and gynecological cancer: an introductory overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29427549" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Linking type 2 diabetes and gynecological cancer: an introductory overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15297160" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Endometrial pathologies associated with postmenopausal tamoxifen treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36245087" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Use of Straighteners and Other Hair Products and Incident Uterine Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26254030" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28188769" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8725706" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8725705" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25004338" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9174435" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Childbearing and mortality from cancer of the corpus uteri.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9626340" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Role of reproductive factors on the risk of endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31412996" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Pregnancy duration and endometrial cancer risk: nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22831825" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28486362" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Breastfeeding and Endometrial Cancer Risk: An Analysis From the Epidemiology of Endometrial Cancer Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18501231" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Cigarette smoking and the risk of endometrial cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25800123" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : A systematic review and meta-analysis of physical activity and endometrial cancer risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20877336" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Physical activity, sedentary behaviours, and the prevention of endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12421870" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Physical activity and cancer prevention: etiologic evidence and biological mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19110217" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Coffee drinking and endometrial cancer risk: a metaanalysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19766982" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Tea consumption and risk of endometrial cancer: a metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21595018" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Green and black tea in relation to gynecologic cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37001577" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30003539" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Obesity surgery and risk of cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28938270" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31451560" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
